Allos Therapeutics Announces Closing of Public Common Stock Offering
29 Maio 2008 - 4:00PM
Business Wire
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today the closing
of its previously announced underwritten public offering of
12,420,000 shares of newly issued common stock at a public offering
price of $5.64 per share. The number of shares issued includes
1,620,000 shares purchased by the underwriters pursuant to their
exercise in full of their overallotment option. The Company
received net proceeds from the offering of approximately $65.2
million, after deducting underwriting commissions and estimated
offering expenses. The Company plans to use the net proceeds from
the financing primarily for clinical and preclinical research and
development of its product candidates, manufacture of clinical
trial material and pre-commercial scale-up activities for PDX,
working capital and general corporate purposes. Merrill Lynch &
Co. acted as sole bookrunner for this offering. Banc of America
Securities LLC and Citigroup Global Markets Inc. acted as co-lead
managers. Copies of the final prospectus relating to the offering
may be obtained from Merrill Lynch & Co., by mail at Merrill
Lynch�s prospectus department at 4 World Financial Center, New
York, New York 10080. The shares were issued pursuant to a shelf
registration statement filed with the Securities and Commission on
May 23, 2007 and declared effective on June 5, 2007. This press
release does not and shall not constitute an offer to sell or the
solicitation of an offer to buy the Company's common stock, nor
shall there be any sale of the common stock in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any state. About Allos Therapeutics, Inc. Allos
Therapeutics is a biopharmaceutical company focused on developing
and commercializing small molecule therapeutics for the treatment
of cancer.�The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in
a pivotal Phase 2 (PROPEL) trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The PROPEL trial is being
conducted under an agreement reached with the U.S. Food and Drug
Administration under its special protocol assessment, or SPA,
process. The Company is also investigating PDX in patients with
non-small cell lung cancer and a range of lymphoma sub-types. The
Company's other product candidate�is RH1, a targeted
chemotherapeutic agent currently being evaluated in a Phase 1 trial
in patients with advanced solid tumors or non-Hodgkin�s lymphoma
(NHL). For additional information, please visit the Company�s
website at www.allos.com. Safe Harbor Statement This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include statements
concerning the amount of the net proceeds, the potential to
complete the Company�s ongoing development programs with the
proceeds of the financing, and other statements which are other
than statements of historical facts. In some cases, you can
identify forward-looking statements by terminology such as "may,"
"will," "should," "expects," "intends," "plans," anticipates,"
"believes," "estimates," "predicts," "projects," "potential,"
"continue," and other similar terminology or the negative of these
terms, but their absence does not mean that a particular statement
is not forward-looking. Such forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that may cause actual results to differ materially
from those anticipated by the forward-looking statements. These
risks and uncertainties include, among others, the risk that
additional capital may be required in the future to complete
on-going trials. Additional information concerning these and other
factors that may cause actual results to differ materially from
those anticipated in the forward-looking statements is contained in
the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2007, the Company's other
periodic reports and filings with the SEC and the prospectus
supplement related to the offering. The Company cautions investors
not to place undue reliance on the forward-looking statements
contained in this press release. All forward-looking statements are
based on information currently available to the Company on the date
hereof, and the Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of this presentation, except as
required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics, Inc.